| Li, Ping |
NCT06381323: The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism |
|
|
| Recruiting | 4 | 55 | RoW | Finerenone, Nifedipine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Primary Aldosteronism, Finerenone, Mineralocorticoid Receptor Antagonist | 03/27 | 04/27 | | |
NCT06256289: Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome |
|
|
| Not yet recruiting | 4 | 50 | NA | Canagliflozin 100mg Tab, Invokana, Metformin Hydrochloride, Glucophage | Ping Li,MD | Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease | 04/25 | 04/25 | | |
NCT04939441: Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) |
|
|
| Active, not recruiting | 4 | 100 | RoW | Tenofovir alafenamide, Vemlidy® | Jidong Jia, Beijing Ditan Hospital, ShuGuang Hospital, Tianjin Third Central Hospital, Huashan Hospital, The Sixth Peoples Hospital of Zhengzhou, Tianjin Second People's Hospital, Ruijin Hospital, Shanghai East Hospital | Chronic Hepatitis B | 05/24 | 05/25 | | |
NCT05814770: Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism |
|
|
| Not yet recruiting | 4 | 96 | NA | Finerenone, Kerendia, Spironolactone | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, National Key Research and Development Program of China, National Natural Science Foundation of China | Primary Aldosteronism, Hypertension | 03/25 | 03/26 | | |
NDKD, NCT06110130: Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With |
|
|
| Recruiting | 4 | 60 | US | Empagliflozin 10 MG, Placebo | Washington D.C. Veterans Affairs Medical Center, Boehringer Ingelheim | Chronic Kidney Diseases | 12/25 | 12/26 | | |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
| Completed | 3 | 533 | RoW | Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage | Chipscreen Biosciences, Ltd. | Type 2 Diabetes | 02/23 | 02/23 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
TRAPP, NCT05811676: Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women with Placenta Previa |
|
|
| Recruiting | 3 | 1680 | RoW | Tranexamic acid, 0.9% sodium chloride | Guangzhou Medical University, Dongguan Maternal and Child Health Care Hospital, Foshan Women and Children Hospital, BoAi Hospital of Zhongshan, Women and Children's Hospital of Chongqing Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Urumqi Maternal and Child Health Care Hospital, Zhuhai Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Hunan Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, Nanfang Hospital, Southern Medical University, Huadu District People's Hospital of Guangzhou, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital, Sun Yat-Sen University, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen Baoan Women's and Children's Hospital, Dongguan People's Hospital, First Affiliated Hospital of Xinjiang Medical University, Tongji Hospital, Peking Union Medical College, Peking University First Hospital, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shijiazhuang Obstetrics and Gynecology Hospital | Hemorrhage, Postpartum, Placenta Previa | 02/25 | 04/25 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
ACHIEVE, NCT04808752: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases |
|
|
| Active, not recruiting | 2 | 63 | RoW | Almonertinib, Investigational Product | Zhejiang Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 06/24 | 07/24 | | |
NCT06677879: A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer. |
|
|
| Recruiting | 2 | 780 | RoW | Proton radiotherapy, Photon radiotherapy | Shanghai Proton and Heavy Ion Center | Breast Cancer | 07/26 | 07/28 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
| Recruiting | 2 | 54 | RoW | proton plus carbon ion radiation | Shanghai Proton and Heavy Ion Center | Prostate Cancer | 05/25 | 05/26 | | |
| Recruiting | 2 | 140 | RoW | carbon ion irradation, Carbon Ion Irradiation With SIB | Shanghai Proton and Heavy Ion Center | Localized Prostate Cancer | 07/25 | 07/28 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
SPHIC-TR-BCa2022-02, NCT05692674: A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction |
|
|
| Recruiting | 2 | 67 | RoW | adjuvant hypofractionated intensity-modulated proton radiotherapy | Shanghai Proton and Heavy Ion Center | Breast Cancer | 09/28 | 09/28 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
| Recruiting | 1 | 30 | RoW | carbon ion radiotherapy | Shanghai Proton and Heavy Ion Center | Radiotherapy, Prostate Cancer | 12/22 | 06/23 | | |
NCT06375161: Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients. |
|
|
| Recruiting | 1 | 12 | RoW | anti-CD19-CAR-T cells | Shanghai Tongji Hospital, Tongji University School of Medicine | B Cell Malignancies | 12/25 | 12/39 | | |
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 41 | RoW | GNC-038 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 06/25 | 11/25 | | |
| Recruiting | 1 | 92 | RoW | TQB2223 injection+ Penpulimab Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 01/25 | 01/26 | | |
NCT05924750: A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 26 | RoW | BL-M11D1 | Sichuan Baili Pharmaceutical Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | 08/25 | 08/25 | | |
| Recruiting | 1 | 24 | RoW | proton plus carbon ion radiotherapy | Shanghai Proton and Heavy Ion Center | Triple Negative Breast Cancer, HER2-positive Breast Cancer | 10/25 | 01/26 | | |
CHESS1901, NCT03990753: Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (/APPHA1901) |
|
|
| Recruiting | N/A | 1000 | RoW | esophagogastroduodenoscopy | Nanfang Hospital of Southern Medical University, Southern Medical University, China, LanZhou University, Zhongda Hospital, Medical School, Southeast University, Guangdong Second Provincial General Hospital, Xingtai People's Hospital, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Tianjin Second People's Hospital, Zhejiang University Lishui Hospital, The Second Hospital of Anhui Medical University, The Sixth People's Hospital of Shenyang, Xi'an Gaoxin Hospital, King Chulalongkorn Memorial Hospital affiliated to Chulalongkorn University, Ankara University | Compensated Cirrhosis | 06/21 | 06/22 | | |
| Not yet recruiting | N/A | 5000 | RoW | Endovascular Therapy | Chinese Academy of Medical Sciences, Fuwai Hospital | Renal Artery Obstruction, Hypertension, Renovascular | 04/22 | 04/24 | | |
NCT04108169: Association Between S-LAAO and Adverse Cardiovascular Events Among Patients Undergoing Coronary Artery Bypass Grafting. |
|
|
| Recruiting | N/A | 240 | RoW | Left atrial appendage occlusion surgery | Beijing Institute of Heart, Lung and Blood Vessel Diseases | Heart Surgery | 10/22 | 01/23 | | |
NCT02739659: Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer |
|
|
| Recruiting | N/A | 73 | RoW | carbon-ion radiotherapy | Shanghai Proton and Heavy Ion Center | Prostate Carcinoma | 12/22 | 12/24 | | |
NCT05392712: Magnetocardiography in the Accurate Identification of Severe Coronary Lesions and Myocardial Necrosis |
|
|
| Recruiting | N/A | 430 | RoW | Magnetometer | Qilu Hospital of Shandong University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Weifang People's Hospital, Linyi People's Hospital, Jining First People's Hospital, The First Affiliated Hospital with Nanjing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing Emergency Medical Center, Guangdong Provincial Hospital of Traditional Chinese Medicine, First People's Hospital of Hangzhou, Central hospital Affiliated to Shandong First Medical University, Weihai Central Hospital, Heze Municipal Hospital | Chest Pain, Acute Coronary Syndrome, Myocardial Infarction | 08/24 | 12/24 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events |
|
|
| Recruiting | N/A | 100000 | RoW | | Chinese Academy of Medical Sciences, Fuwai Hospital | Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment | 12/22 | 12/23 | | |
NCT04833192: Evaluation of New Diagnostic Indicator of Subclinical Hypercortisolism |
|
|
| Recruiting | N/A | 202 | RoW | experimental group | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Adrenal Incidentaloma, Subclinical Hypercortisolism | 04/23 | 12/23 | | |
NCT05826080: Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism |
|
|
| Recruiting | N/A | 59 | RoW | | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Primary Aldosteronism, Aldosterone-Producing Adenoma, Idiopathic Hyperaldosteronism | 10/23 | 09/24 | | |
NCT05896826: Magnetocardiography in the Accurate Identification of Myocardial Infarction |
|
|
| Recruiting | N/A | 500 | RoW | Magnetometer | Qilu Hospital of Shandong University, Chongqing Emergency Medical Center, Weifang People's Hospital, Linyi People's Hospital, Weihai Central Hospital, Jining First People's Hospital, The First Affiliated Hospital with Nanjing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital Xi'an Jiaotong University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Central hospital Affiliated to Shandong First Medical University, Heze Municipal Hospital, First People's Hospital of Hangzhou | Chest Pain, Acute Coronary Syndrome, Myocardial Infarction | 10/24 | 12/24 | | |
| Recruiting | N/A | 240 | RoW | Carvedilol 12.5 MG, Nucleos(t)ide Analogues | Beijing Friendship Hospital | Liver Cirrhosis, Portal Hypertension | 10/24 | 10/24 | | |
TAILOR-TAVR, NCT05511792: Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0) |
|
|
| Recruiting | N/A | 206 | RoW | TAVR for BAV Using Down Sizing with the Evolut Pro platform, Down Sizing Strategy, TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform, Standard Sizing Strategy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Aortic Stenosis With Bicuspid Valve | 06/25 | 06/29 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT03261934: Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation |
|
|
| Recruiting | N/A | 2000 | RoW | No intervention | Beijing University of Chinese Medicine, The University of Science and Technology of China, China Academy of Chinese Medical Sciences, Harvard Medical School (HMS and HSDM) | Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation | 12/30 | 12/30 | | |
ACTRN12622000019707: Effects of recorded maternal voice on heart rate and anthropometric parameters in premature infants: A randomized controlled trial |
|
|
| Completed | N/A | 108 | | | Ping Li, Ping Li | heart rate, anthropometric parameters | | | | |
NCT04289701: Hypertension Registry of "Hypertension Prevention and Control Initiative in China" |
|
|
| Recruiting | N/A | 200000 | RoW | Health Services for Systematic Hypertension Management | Chinese Academy of Medical Sciences, Fuwai Hospital | Hypertension | 12/22 | 12/24 | | |
NCT05357456: Performances on Cognitive Functions and Brain Function and Follow-up After Different Treatments in Patients With Autonomous Cortisol Secretion: a Single-center, Prospective, Observational Study |
|
|
| Recruiting | N/A | 62 | RoW | Cognitive function assessment; functional magnetic resonance imaging, fMRI, laparoscopic adrenal surgery | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Autonomous Cortisol Secretion, Adrenal Incidentaloma, Non-functioning Adrenal Adenomas | 10/24 | 10/26 | | |
| Zhang, Fan |
ESPTTN, NCT06423235: Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules |
|
|
| Not yet recruiting | 4 | 426 | RoW | regular dose of JiRui® Prunella oral liquid, 2x regular dose of JiRui® Prunella oral liquid, regular dose of placebo, 2x regular dose of placebo | Xintian Pharmaceutical | Thyroid Nodule | 07/25 | 07/28 | | |
NCT05812014: Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older |
|
|
| Recruiting | 3 | 9800 | RoW | SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution | AIM Vaccine Co., Ltd., LiveRNA Therapeutics Inc., Ningbo Rongan Biological Pharmaceutical Co. Ltd. | SARS-CoV-2 | 03/24 | 06/24 | | |
RECAST-MT, NCT06559241: Remote Ischemic Conditioning for Acute Ischemic Stroke Treated with Mechanical Thrombectomy（） |
|
|
| Recruiting | 3 | 2105 | RoW | 14-day remote ischemic conditioning, 14-day RIC, 30-day remote ischemic conditioning, 30-day RIC, Endovascular thrombectomy, EVT, Best medical management | Capital Medical University | Acute Ischemic Stroke, Anterior Circulation Brain Infarction | 11/26 | 02/27 | | |
INSPIRE-BDLL, NCT06649721: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort |
|
|
| Not yet recruiting | 3 | 120 | RoW | bedaquiline, BDQ, B, delamanid, DLM, D, linezolid, LZD, L, Levofloxacin, LFX, Clofazimine, CFZ, C | Huashan Hospital, Beijing Chest Hospital | Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis | 06/27 | 06/27 | | |
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort |
|
|
| Recruiting | 3 | 186 | RoW | Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB | Beijing Chest Hospital, National Medical Center for Infectious Diseases | Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | 10/26 | 12/26 | | |
NCT02029937: High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia |
|
|
| Recruiting | 2 | 1300 | US, RoW | Proflavine, high resolution imaging, Proflavine hemisulfate | Anandasabapathy, Sharmila, M.D., William Marsh Rice University, Baylor College of Medicine | Suspected or Known Squamous Cell Neoplasia, Prior History of Squamous Cell Dysplasia and /or Neoplasia | 12/21 | 12/21 | | |
NCT05939648: A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) |
|
|
| Active, not recruiting | 2 | 450 | RoW | SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline | AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co., Ltd. | SARS-CoV-2 | 11/23 | 12/24 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
NCT05939596: A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) |
|
|
| Active, not recruiting | 1 | 60 | RoW | SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline | AIM Vaccine Co., Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 09/23 | 08/24 | | |
NCT06773286: Combining Spinal Cord Transcutaneous Stimulation and Activity-based Training in Inpatient Rehabilitation to Facilitate Upper Limb Function of Individuals with Acute to Subacute Cervical Spinal Cord Injury |
|
|
| Recruiting | N/A | 30 | US | Active Stimulation, Sham, Training only | Kessler Foundation | Spinal Cord Injury Cervical | 12/25 | 12/25 | | |
NCT05845372: Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy |
|
|
| Not yet recruiting | N/A | 2592 | RoW | | Nanfang Hospital of Southern Medical University, The Fourth Affiliated Hospital of Guangzhou Medical University, The Affiliated Hospital of Inner Mongolia Medical University, Second Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Guangxi Medical University, Fujian Medical University Union Hospital, Huizhou Municipal Central Hospital, Haikou People's Hospital, Kashgar 1st People's Hospital, Ganzhou City People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Huadu District People's Hospital of Guangzhou, Dongguan donghua hospital, Sinopharm North Hospital, Heyuan people's Hospital, Hainan People's Hospital, Hainan Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, The Second Hospital University of South China, Dongguan People's Hospital, Yueyang People's Hospital | Acute Ischemic Stroke | 01/27 | 01/27 | | |
NCT05914272: Association of Osmotic Drugs With Clinical Outcomes in Acute Large Hemispheric Infarction |
|
|
| Not yet recruiting | N/A | 2592 | RoW | Osmotic drugs | Nanfang Hospital of Southern Medical University, The Second Hospital University of South China, The Affiliated Hospital of Inner Mongolia Medical University, Second Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Guangxi Medical University, Fujian Medical University Union Hospital, Huizhou Municipal Central Hospital, Haikou People's Hospital, Kashgar 1st People's Hospital, Ganzhou City People's Hospital, The Fourth Affiliated Hospital of Guangzhou Medical University, Dongguan People's Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Hainan Traditional Chinese Medicine Hospital, Hainan People's Hospital, Sinopharm North Hospital, Huadu District People's Hospital of Guangzhou, Guangdong Provincial Hospital of Traditional Chinese Medicine | Stroke | 01/27 | 01/27 | | |
| Yuan, Hong |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT04861922: Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection |
|
|
| Recruiting | 3 | 100 | RoW | Unfractionated Heparin, Heparin sodium | The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, Central South University, The Second Hospital of South China University, Wuhan Union Hospital, China, The Affiliated Yantai Yuhuangding Hospital of Qingdao University | Sepsis, Gram-Negative Bacterial Infections, Heparin | 12/23 | 07/24 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT04289701: Hypertension Registry of "Hypertension Prevention and Control Initiative in China" |
|
|
| Recruiting | N/A | 200000 | RoW | Health Services for Systematic Hypertension Management | Chinese Academy of Medical Sciences, Fuwai Hospital | Hypertension | 12/22 | 12/24 | | |
| Zhao, Fengli |
NCT03789760: The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule |
|
|
| Completed | 3 | 493 | RoW | SaiLuoTong capsule, The effects of SaiLuoTong capsule on VaD, placebo | Shineway Pharmaceutical Co.,Ltd | Vascular Dementia | 03/24 | 05/24 | | |
NCT05630573: A Study of TNM001 in Chinese Healthy Preterm and Term Infants |
|
|
| Completed | 1/2 | 31 | RoW | TNM001, Placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 06/23 | 06/23 | | |
NCT05364047: Clinical Trial of SARS-CoV-2 mRNA Vaccine in China |
|
|
| Active, not recruiting | 1 | 144 | RoW | Low-dose of LVRNA009, Middle-dose of LVRNA009, High-dose of LVRNA009, Placebo | AIM Vaccine Co., Ltd., Shulan (Hangzhou) Hospital, Yuncheng Central Hospital | COVID-19 | 10/22 | 10/23 | | |
| niu, zhaofeng |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
| Wang, Binglong |
NCT04948502: SaExten Vena Cava Filter System in Prevention of Pulmonary Embolism |
|
|
| Completed | N/A | 192 | RoW | SaExten vena cava filter system, SaExten VCF system, Denali inferior vena cava filter, Denali IVCF | ShenZhen KYD Biomedical Technology Co., Ltd. | Pulmonary Embolism | 01/22 | 09/22 | | |
| Tian, Qiuju |
NCT05532345: Discrimination of DILI and AIH by Artificial Intelligence |
|
|
| Completed | N/A | 2583 | RoW | | Beijing Friendship Hospital | Drug-induced Liver Injury, Autoimmune Hepatitis | 05/23 | 05/23 | | |
| Recruiting | N/A | 3000 | RoW | | Beijing Friendship Hospital | Drug-induced Liver Injury | 12/26 | 12/28 | | |
NCT05086536: Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis |
|
|
| Not yet recruiting | N/A | 600 | RoW | no intervention | Beijing Friendship Hospital, Beijing YouAn Hospital, Shandong Provincial Hospital, The Affiliated Hospital of Qingdao University, The First Affiliated Hospital of Shanxi Medical University, Xiangya Hospital of Central South University, The Second Affiliated Hospital of Baotou Medical College | Hepatitis B, Decompensated Cirrhosis | 06/22 | 12/22 | | |
| Chen, Guiling |
NCT05365724: A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above |
|
|
| Active, not recruiting | 1/2 | 280 | RoW | Omicron COVID-19 Vaccine (Vero Cell), Inactivated | China National Biotec Group Company Limited, Beijing Institute of Biological Products Co Ltd., Shulan (Hangzhou) Hospital | COVID-19 | 10/23 | 10/23 | | |
NCT05354089: A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years. |
|
|
| Active, not recruiting | 1 | 40 | RoW | 20 μg dose of SYS6006, 30 μg dose of SYS6006, Placebo | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | SARS-CoV-2 | 07/22 | 10/23 | | |
NCT05354063: A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults. |
|
|
| Active, not recruiting | 1 | 40 | RoW | 20 μg dose of SYS6006, 30 μg dose of SYS6006, Placebo | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | SARS-CoV-2 | 09/22 | 10/23 | | |
NCT05364047: Clinical Trial of SARS-CoV-2 mRNA Vaccine in China |
|
|
| Active, not recruiting | 1 | 144 | RoW | Low-dose of LVRNA009, Middle-dose of LVRNA009, High-dose of LVRNA009, Placebo | AIM Vaccine Co., Ltd., Shulan (Hangzhou) Hospital, Yuncheng Central Hospital | COVID-19 | 10/22 | 10/23 | | |
NCT05449535: Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects |
|
|
| Completed | 1 | 56 | RoW | JYB1904, Omalizumab, Xolair, JYB1904 Placebo | Jemincare | Healthy | 01/23 | 01/23 | | |
NCT06113744: A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine |
|
|
| Recruiting | 1 | 164 | RoW | Placebo, COVID-19 Vaccine (Vero Cell) ,Inactivated, COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg, COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg, COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg | CNBG-Virogin Biotech (Shanghai) Ltd., Shulan (Hangzhou) Hospital | SARS-CoV-2 Infection | 06/23 | 06/24 | | |
| Hao, Chenhui |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
| Qu, Yanling |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
| Recruiting | 3 | 405 | Europe, Canada, US, RoW | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
| Turbay, David |
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD |
|
|
| Recruiting | 3 | 400 | US | TQJ230, pelacarsen, Placebo | Novartis Pharmaceuticals | Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | 03/27 | 03/27 | | |
| Recruiting | 3 | 1328 | Europe, Canada, US, RoW | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/26 | 10/26 | | |
| Recruiting | 3 | 405 | Europe, Canada, US, RoW | Plozasiran Injection, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Severe Hypertriglyceridemia | 07/26 | 10/26 | | |
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension |
|
|
| Enrolling by invitation | 3 | 1400 | Europe, Canada, US, RoW | lorundrostat, Placebo | Mineralys Therapeutics Inc. | Hypertension | 12/25 | 12/26 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
|
|
| Active, not recruiting | 3 | 17004 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 10/27 | 10/27 | | |
| Active, not recruiting | 3 | 14013 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 04/29 | 04/29 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Active, not recruiting | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 02/25 | | |
| Duan, Lixiang |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
| Cheng, Dapeng |
NCT05664750: Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus |
|
|
| Completed | 3 | 675 | RoW | TNM002, Human tetanus immunoglobulin (HTIG) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Tetanus | 03/23 | 07/23 | | |
NCT06635798: A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection |
|
|
| Recruiting | 3 | 582 | RoW | GR2001, HTIG | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Tetanus | 12/24 | 03/25 | | |
| Wang, Lihe |
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
|
|
| Not yet recruiting | 2b | 2250 | RoW | TNM001, placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 05/26 | 08/26 | | |
| Wang, Xiaojing |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
| Fan, Juanli |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
